Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 mAb are continuall...

Full description

Bibliographic Details
Main Authors: Beers, Stephen A. (Author), French, Ruth R. (Author), Chan, Claude H.T (Author), Lim, Sean H. (Author), Jarrett, Timothy C. (Author), Mora Vidal, Regina (Author), Wijayaweera, Sahan S. (Author), Dixon, Sandra V. (Author), Kim, Hyung J. (Author), Cox, Kerry L. (Author), Kerr, Jonathan P. (Author), Johnston, David A. (Author), Johnson, Peter W.M (Author), Verbeek, Sjef (Author), Glennie, Martin J. (Author), Cragg, Mark S. (Author)
Format: Article
Language:English
Published: 2010-02-22.
Subjects:
Article
Online Access:Get fulltext

Similar Items

Similar Items